Rituximab | sciencenewsnet.in

Breaking News

MSU researchers receive $4M NIH grant to study dementia risks

E-Cigarette Residue Exposure in Utero Shows Lasting Effects on Immune Response

Scientists discover ‘entirely unanticipated’ role of protein netrin1 in spinal cord development

What happens if the Department of Education disappears? Expert warns how it could threaten quality, student mobility and more.

Drug Combination Prompts Immune Response in Some Resistant Pancreatic Cancers

NASA’s Hubble Sees Aftermath of Galaxy’s Scrape with Milky Way

MSU expert: Diseases threaten deer populations

Woods Hole Oceanographic Institution and Brazilian State of Pará sign Memorandum of Understanding in advance of COP30

New Study Highlights Urgent Need for Targeted Suicide Prevention and Mental Health Support for Sexual and Gender Diverse Youth

ETRI, Demonstration of 8-Photon Qubit Chip for Quantum Computation

15 Nov, 2024

Patients taking Rituximab Could Benefit from Third COVID-19 Vaccine Dose

November 1, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

Ultra-Low Dose Rituximab Controls Disease Activity for Most RA Patients in New Study

November 1, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.